• Citer

Adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma: a phase III randomized controlled trial of health-related quality of life and symptoms by the European Organisation for Research and Treatment of Cancer Melanoma Group.

par Bottomley, Andrew;Coens, Corneel;Suciu, Stefan ;Santinami, M.;Kruit, Willem;Testori, Alessandro;Marsden, Jeremy;Punt, Cornelis;Sales, François ;Gore, Martin;Mackie, Rona;Kusic, Zvonko;Dummer, Reinhard;Patel, Poulam;Schadendorf, Dirk;Spatz, Alain;Keilholz, Ulrich;Eggermont, A
Référence Journal of clinical oncology, 27, 18, page (2916-2923)
Publication Publié, 2009-06

Article révisé par les pairs

• Détails
• Contenu

Titre:	Adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma: a phase III randomized controlled trial of health-related quality of life and symptoms by the European Organisation for Research and Treatment of Cancer Melanoma Group.
Auteur:	Bottomley, Andrew; Coens, Corneel; Suciu, Stefan; Santinami, M.; Kruit, Willem; Testori, Alessandro; Marsden, Jeremy; Punt, Cornelis; Sales, François; Gore, Martin; Mackie, Rona; Kusic, Zvonko; Dummer, Reinhard; Patel, Poulam; Schadendorf, Dirk; Spatz, Alain; Keilholz, Ulrich; Eggermont, A
Informations sur la publication:	Journal of clinical oncology, 27, 18, page (2916-2923)
Statut de publication:	Publié, 2009-06
Sujet CREF:	Cancérologie
MeSH keywords:	Chemotherapy, Adjuvant -- methods
	Female
	Humans
	Interferon-alpha -- therapeutic use
	Male
	Melanoma -- drug therapy -- mortality
	Middle Aged
	Neoplasm Staging
	Polyethylene Glycols
	Quality of Life
	Recombinant Proteins
	Skin Neoplasms -- drug therapy -- mortality
Note générale:	Clinical Trial, Phase III
	Journal Article
	Randomized Controlled Trial
	Research Support, Non-U.S. Gov't
Langue:	Anglais
Identificateurs:	urn:issn:0732-183X
	info:doi/10.1200/JCO.2008.20.2069
	info:pii/JCO.2008.20.2069
	info:pmid/19433686